AEGON LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.816 EUR | -0.80% |
|
-1.73% | +10.67% |
| 06-25 | Transcript : Aegon Ltd. - Special Call | |
| 06-12 | Transcript : Aegon Ltd. - Shareholder/Analyst Call |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Its low valuation, with P/E ratio at 7.97 and 6.97 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- The company's share price in relation to its net book value makes it look relatively cheap.
- The company is one of the best yield companies with high dividend expectations.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Life & Health Insurance
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +10.67% | 10.83B | - | ||
| +3.66% | 72.1B | B- | ||
| +8.25% | 50.75B | B | ||
| +6.14% | 49.91B | B+ | ||
| +24.42% | 47.64B | B+ | ||
| +13.00% | 42.08B | B+ | ||
| +21.91% | 38.54B | B | ||
| +17.16% | 33.02B | B | ||
| -2.39% | 28.42B | B | ||
| -9.01% | 27.19B | B- |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- AGN Stock
- AGN Stock
- Ratings Aegon Ltd.
